REVENUE (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Summary of net revenue

The following table reflects summary revenue, net for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Product sales, net:
CAMBIA	$	7,780	$	6,758	$	14,054	$	15,566
Zipsor	3,535		1,524		5,866		5,755
INDOCIN products(1)	5,434		—		5,434		—
SPRIX Nasal Spray(1)	1,602		—		1,602		—
SOLUMATRIX products(1)	836		—		836		—
OXAYDO(1)	517		—		517		—
Gralise	(116)		17,800		431		31,078
NUCYNTA and Lazanda product sales adjustments	577		(145)		677		(12)
Total product sales, net	20,165		25,937		29,417		52,387
Commercialization agreement, net	—		31,003		11,258		61,859
Royalties and milestone revenue	452		263		859		886
Total revenues	$	20,617	$	57,203	$	41,534	$	115,132

(1)Products acquired in connection with Zyla Merger represent product sales, net for the period of May 20, 2020 through June 30, 2020.

Summary of changes in contract assets

The following table reflects changes in the Company’s contract assets as of June 30, 2020 (in thousands):

	Balance as of			Balance as of
	December 31, 2019	Additions	Deductions	June 30, 2020
Contract asset - Collegium, net	1,896	—	(1,896)	—